CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells

(2011) A Dar et al.   LEUKEMIA

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

Identification of Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-1/CXCR4 Axis

(2011) Itaru Kato et al.   PLoS One

Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells

(2010) Iskra Pusic et al.   CURRENT OPINION IN HEMATOLOGY

The leukemic stem cell niche: current concepts and therapeutic opportunities

(2009) S. W. Lane et al.   BLOOD

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

(2008) S. M. Devine et al.   BLOOD

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

CXCR4 is required for the quiescence of primitive hematopoietic cells

(2008) Yuchun Nie et al.   JOURNAL OF EXPERIMENTAL MEDICINE